Welcome to 5 th Munich Biomarker Conference

Transcription

1 Clinical Practice and Targeted Therapies in Personalized Medicine Welcome to 5 th Munich Biomarker Conference December 1 st 2 nd, 2015 RAMADA Hotel & Conference Center München Messe

2 We thank our sponsors

3 We thank our sponsors

4 Bavaria: from tradition

5 to innovation

6 There are more than 345 biotech and pharma companies in Bavaria More than 345 biotech & pharma companies, of which 170 are SME 7 approved drugs from German biotechnology companies on the global market 40,000 employees in biotech & pharma & academia 8.3 billion in revenues p.a., 580 mio. from biotech-sme > 3.5 billion invested in biotech since

7 With 30,000 employees working in the industry, Bavaria is a top European biotechnology cluster* Total revenues 30,000 11,500 Bio(tech)/Pharma + 5.6% compared to 2013 Biotechnology (alone) + 4.3% compared to 2013 *Genetic Engineering and Biotechnology News

8 Bavarian biotech SME focus on therapeutics and diagnostics Bavarian Biotech SME - area of work Major indications 61 Biotech Therapeutics & Diagnostics Biotech Devices & Reagents Biotech Agro, Food, Environment Other 2 Autoimmune 3 CNS Biotech Bioinformatics Biotech DNA/Protein Analytics Infectiology 5 Oncology 8

9 Bavaria s drug development pipeline is filled with 65 drug candidates in clinical development Marketed Drugs (derived from SME) Source: Bavarian Biotech Report 2014/15 9

10 Bavaria provides an excellent academic life science environment with cutting edge research 10

11 Bio M is the cluster development organization for Munich and Bavaria Würzburg Companies:22 Space: > 4000 sqm Regensburg Companies:44 Space: > sqm Erlangen Companies:>30 Space: > sqm Straubing Companies:9 Space: >1.200 sqm Martinsried Companies: 70 Size: sqm Weihenstephan Companies: 7 Space: sqm 11

12 All national health centers are (co)located in Bavaria s capital Munich 12

13 Bio M and Munich Biotech Cluster at a Glance 13

14 Bio M accelerating biomedical innovation Professional Biotech Cluster Management since 1997 Bio M is the central point of contact for medical biotechnology in Munich and Bavaria. The major goal of Bio M is to foster the sustainable development of the Munich & Bavarian Biotech Cluster and expand its position as one of the leading life science clusters in Europe. With its outstanding and broad network and services, Bio M is a valuable partner for biotech SME, academia / clinicians, pharma and investors. Bio M is a non-profit organisation and funded by the Bavarian State Ministry of Economic Affairs, Media, Energy and Technology. 14

15 Bio M accelerating biomedical innovation Central contact point for research, entrepreneurs & companies SME Big Pharma Academia Funding Advices Partnering Business Development Networking Seminars & Workshops Scouting & Incubation Start-up Consulting Information Events Lobbying 15

16 Bio M serves as an incubator and fosters biomedical innovation Bio M Award Bio M Mentor Circle Bio M Incubation Bio M Pitch Training Bio M BioEntrepreneur Lounge Bio M BioEntrepreneur Bootcamp 16

17 The Munich Biotech Cluster Success stories founded in 2011 as spin-off of the Technical University of Munich TUM Unique biological format: anticalin therapeutics In April 2011, Pieris signs discovery deal with Daiichi Sankyo worth 207 million In December 2014, Pieris goes public in a reverse merger transaction, NASDAQ listing in 2015 (Pieris Inc.) founded 2005 as a spin-off of the Max Planck Institute for Biochemistry Fc-gamma receptor IIb based protein therapeutics to treat autoimmune diseases and allergies In March 2015, Baxter Bioscience acquires SuppreMol in a transaction value of 200 million founded 2001 as a spin-off of the Max Planck Institute for Biochemistry monoclonal antibodies to treat cancer In May 2008 Daiichi Sankyo acquires U3 Pharma in a cash transaction worth 150 million founded as a spin-off of the LMU Munich in 1996 BiTE antibodies (Bispecific T-cell Engagers) In January 2012, Amgen acquired Micromet in a cash transaction worth $ 1.16 billion 2014: FDA Breakthrough designation for Blinatumomab US approval in late 2014 ( Blincyto ) founded as a spin-off from the universities of Würzburg and Tuebingen in 2006 Cyclopeptide for the treatment of heart insufficiency In June 2012, JANSSEN-CILAG acquired Corimmun in a transaction value of $ 100 million

18 Leading-Edge Cluster Munich m 4 Personalized Medicine Winner in the national leading edge cluster competition 5 year funding by BMBF In total about 100 mio for Personalized Medicine ( ) 50 research projects + 6 structural projects >100 partners involved Vision for 2020: Center of Excellence for Personalized Medicine

19 Bio M Connecting the Cluster Partners

20 50 R&D Projects along the Value Chain Biotech SME Pharma industry Academia Clinics Research Preclinic Clinical phases I - III Approval Market Biomarker identification & validation Value-added chain in personalized medicine Test development Test Kit Approval Market

21 50 m 4 R&D-Projects 21 preclinical development projects of new therapeutics 5 clinical trials 11 diagnostic R&D projects 13 biomarker identification projects U3 Pharma Indications: oncology (17) autoimmune diseases (5) cardiovascular diseases (2) neurological diseases (3) infectious diseases (3) Schimpf, RCI 4SC AG

22 Bio M recognizes the challenges of the medicine of the future and supports its development by identifying and connecting the appropriate partners from science, industry, medicine and finance. Bio M accompanies the innovation process by developing and providing target-oriented measures and custom-fit instruments. our action and tool for you: the Munich Biomarker Conference! Bio M Biotech Cluster Development GmbH Am Klopferspitz 19 a I Martinsried-Munich I Germany Phone.: +49 (0) I Fax: +49 (0) info@bio-m.org

23 Exhibitor List Abcam plc Agilent Technologies Affymetrix Austrian Institute of Technology (AIT) Bavarian Research Alliance (BayFor) BioM Biotech Cluster Development Biobank der Blutspender BIOCRATES Life Sciences BioPark Regensburg Bio-Rad Laboratories BioSysNet Cryoshop FibroTx ForBiMed Forschungsverbund Formulatrix Hamilton Robotics Innovations und Gründerzentrum Würzburg (IGZ) Luminex Merck Millipore Miltenyi Biotec National Biological Service (NBS) Pateris Personalis ProteinSimple RainDance Technologies tebu-bio Tepnel Pharma Services